Pharmacogenetics of Drug Therapies in Rheumatoid Arthritis

Atinuke Aluko, Prabha Ranganathan

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

1 Scopus citations

Abstract

Rheumatoid arthritis (RA) is a chronic systemic inflammatory disorder that can lead to severe joint damage and is often associated with a high morbidity and disability. Disease-modifying anti-rheumatic drugs (DMARDs) are the mainstay of treatment in RA. DMARDs not only relieve the clinical signs and symptoms of RA but also inhibit the radiographic progression of disease and reduce the effects of chronic systemic inflammation. Since the introduction of biologic DMARDs in the late 1990s, the therapeutic range of options for the management of RA has significantly expanded. However, patients’ response to these agents is not uniform with considerable variability in both efficacy and toxicity. There are no reliable means of predicting an individual patient’s response to a given DMARD prior to initiation of therapy. In this chapter, the current published literature on the pharmacogenetics of traditional DMARDS and the newer biologic DMARDs in RA is highlighted. Pharmacogenetics may help individualize drug therapy in patients with RA by providing reliable biomarkers to predict medication toxicity and efficacy.

Original languageEnglish
Title of host publicationMethods in Molecular Biology
PublisherHumana Press Inc.
Pages527-567
Number of pages41
DOIs
StatePublished - 2022

Publication series

NameMethods in Molecular Biology
Volume2547
ISSN (Print)1064-3745
ISSN (Electronic)1940-6029

Keywords

  • Azathioprine
  • Methotrexate
  • Pharmacogenetics
  • Polymorphisms
  • Rheumatoid arthritis
  • Rituximab
  • Sulfasalazine
  • Tocilizumab
  • Tumor necrosis factor antagonists

Fingerprint

Dive into the research topics of 'Pharmacogenetics of Drug Therapies in Rheumatoid Arthritis'. Together they form a unique fingerprint.

Cite this